PR – Publications – Media - Events

Media

Interview avec Ernest Loumaye, CEO d’ObsEva / Sphère Oct-Dec 2018

October 12, 2018

Read more

ObsEva: A Small Biotech With a Promising Pipeline – Barron’s

September 14, 2018

Read more

Le Temps – La biotech genevoise ObsEva entre à la bourse suisse

July 12, 2018

Read more

24heures: Depuis Genève, ObsEva lutte contre l’infertilité

July 7, 2018

Read more

Are you sure you want to leave ObsEva.com?

We're sorry to see you go.
Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue